China Medical University Hospital (CMUH) Launches “Intelligent Microbiome Evaluation- iME” to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health
Gastrointestinal (GI) examinations can be invasive or non-invasive. Stool tests (non-invasive) can be associated with limitations such as the amount of pathogens present being too low for culture or detection, resulting in negative PCR results. China Medical University Hospital (CMUH) is…
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both…
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Today, Ajinomoto Co., Inc. (“Ajinomoto Co.”) (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC)…
Angel Yeast Hosts Community Welfare Activity in Egypt, Promoting Green Development and Cultural Exchanges
Angel Yeast, (SH600298), the world’s leading yeast manufacturer, recently hosted a community Welfare Activity on sustainable and green development for the students at a school near its factory in Egypt and gave gifts to the students. As a socially responsible company, Angel Yeast is…
Cureskin secures USD 20 million in Series B funding led by HealthQuad with participation from existing investors including JSW Ventures, Khosla Ventures and Sharrp Ventures
Cureskin, an AI-driven dermatology platform that provides clinically validated skin & hair health solutions, has raised Series B funding of USD 20 million. The round was led by India’s leading digital health-focused venture capital fund, HealthQuad along with participation from…
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announces encouraging data with orally available small molecule GAL-201, showing…
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been dosed in Australia in a first-in-human (FIH) phase…
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has obtained prequalification (PQ) certification from the World Health Organization (WHO) for its typhoid conjugate vaccine (TCV),…
Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into agreements with VBI Vaccines, Inc….
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fourth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor…
